Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chromadex (CDXC)
NASDAQ:CDXC
Chromadex (CDXC) Stock Price & Analysis
409 Followers
CDXC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.25 - $4.65
Previous Close$3.85
Volume438.86K
Average Volume (3M)283.80K
Market Cap
$289.94M
Enterprise Value$293.88M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)-58.4
Beta1.08
Next Earnings
May 09, 2024EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding75,309,118
10 Day Avg. Volume441,850
30 Day Avg. Volume283,796
Standard Deviation0.33
R-Squared0.10
Alpha0.00554
Financial Highlights & Ratios
Price to Book (P/B)10.92
Price to Sales (P/S)4.02
Price to Cash Flow (P/CF)22.10
P/FCF Ratio21.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit6.87
Enterprise Value/Ebitda185.06
Forecast
1Y Price Target
$6.00Price Target Upside55.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Chromadex News
PremiumCompany Announcements
Chromadex Releases Insightful Corporate Presentation Online
Ownership Overview
31.62% Insiders
5.02% Mutual Funds
4.17% Other Institutional Investors
59.18% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CDXC FAQ
What was Chromadex’s price range in the past 12 months?
Chromadex lowest stock price was $1.25 and its highest was $4.65 in the past 12 months.
What is Chromadex’s market cap?
Currently, no data Available
When is Chromadex’s upcoming earnings report date?
Chromadex’s upcoming earnings report date is May 09, 2024 which is in 23 days.
How were Chromadex’s earnings last quarter?
Chromadex released its earnings results on Mar 06, 2024. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.022.
Is Chromadex overvalued?
According to Wall Street analysts Chromadex’s price is currently Undervalued.
Does Chromadex pay dividends?
Chromadex does not currently pay dividends.
What is Chromadex’s EPS estimate?
Chromadex’s EPS estimate is -$0.02.
How many shares outstanding does Chromadex have?
Chromadex has 75,309,120 shares outstanding.
What happened to Chromadex’s price movement after its last earnings report?
Chromadex reported an EPS of $0 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went down -8.046%.
Which hedge fund is a major shareholder of Chromadex?
Among the largest hedge funds holding Chromadex’s share is Gamco Investors, Inc. ET AL. It holds Chromadex’s shares valued at 374K.
---
Chromadex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (55.84% Upside)
$6.00 (55.84% Upside)
Blogger Sentiment
Bullish
CDXC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 295.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.0%
Last 30 Days ▲ 36.4%
Last 30 Days ▲ 36.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
173.04%
12-Months-Change
Fundamentals
Return on Equity
-17.29%
Trailing 12-Months
Asset Growth
1.68%
Trailing 12-Months
Company Description
Chromadex
Chromadex Corp. is a nutraceutical company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Irvine, CA.
---
CDXC Company Deck
---
CDXC Earnings Call
Q4 2024
0:00 / 0:00
---
CDXC Stock 12 Months Forecast
Average Price Target
$6.00
▲(55.84% Upside)
Technical Analysis
Best Analysts Covering CDXC
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+60.07%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +60.07% per trade.
---